Skip to main content

Introduction to Artificial Intelligence in Drug Development (Part 1 and 2)

Introduction to Artificial Intelligence in Drug Development (Part 1 and 2)

Introduction to Artificial Intelligence - Part 2
Date: April 29, 2021
Time: 06:00 PDT | 09:00 AM EDT | 15:00 CET | 18:30 IST


SCDM is organizing a a webinar series on Artificial Intelligence (AI) to help all Drug Development stake holders understand what significant impact it may have in future including to our journey toward Clinical Data Science. It is therefore important to start understanding what it is, what role it may have, the different between Intelligent and traditional solutions, its development life cycle and potential regulatory implications.

This webinar is a first step to support our Drug Development community comprehend a key component of our future: AI!


  • Key terms, their definitions and differences
  • Traditional vs. AI programming AI/ ML Algorithms
  • Applicability to Life Sciences: Global Drug Development (GDD) processes
    Regulatory point of view
  • Share a case study


SCDM Community and all Drug Development Stakeholders including Quality Experts and Inspectors.


Start understanding what AI is and its implication to the Drug Development ecosystem


Jonathan Andrus, M.S., CQA, CCDM, Chief Business Officer, Clinical Ink, Inc.
As chief business officer, Jonathan Andrus leads Clinical Ink’s solution management and commercial teams to help sponsors and CROs better leverage eSource, eCOA, and ePRO data. With more than 25 years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution. At Clinical Ink, Mr. Andrus is responsible for P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies, and clinical research professionals.

Within SCDM, Jonathan, over the past 14 years on the board:
  • Served as SCDM Chair - 2008 and 2013
  • Serves as regulatory liaison and annual regulatory town hall host
  • Serves as SCDM Treasurer and Executive Committee Member

Demetris Zambas, Head of Data Monitoring and Management
Demetris is currently VP and Global Head of Data Monitoring and Management at Pfizer. Demetris started his career as a Laboratory Scientist in 1991 and transitioned into the Clinical Development space where he held roles of increasing responsibilities in Trial Management and Monitoring and led the implementation of the company’s first Clinical Trial Management system. In 2000, Demetris was a member and eventually the leader of the team which executed the industry’s first Tech- Transfer of a web based EDC system. He eventually led the Data Management and Standards organization and continued on to Merck & Co. following the merger in 2009. Subsequently Demetris was Vice President of Data Management at Novartis AG from 2014 to 2017. Since 2017 Demetris leads Pfizer’s Data Management and Risk Based Monitoring line functions in a new transformation; developing and transitioning into an internal operating model across multiple geographic sites in support of Pfizer’s portfolio. He also leads the Data and Automation work stream as part of Pfizer’s Development-wide transformation effort. He currently serves on multiple Boards, including SCDM’s Advisory Board, has served on the Board of Trustees and was the 2016 Chair.

Prasanna Rao, Head, Artificial Intelligence and Data Science
Prasanna Rao is an AI practitioner and Industry Thought Leader whose current role is the Head of Artificial Intelligence and Data Science for Data Management and Monitoring at Pfizer. He has over 25 years of experience in Information technology and Analytics, with 10 years in Healthcare and Life Sciences. He has implemented several AI projects in the last 8 years including projects with IBM Watson Health, as a Watson Solution Architect. His role at Pfizer is to analyze Clinical Development use cases, carefully evaluate various AI/ML techniques, conduct hackathons, and implement AI & automation solutions to deliver business value.

Ashley Howard Associate Director, Asset Lead, Pfizer
An experienced data manager leader Ashley has worked across therapeutic area disciplines within both the pharmaceutical and CRO industries. With over 11 years’ experience in Clinical Data Management Ashley started his career in the late phase Data Management department at PAREXEL. He progressed into a Data Management operational leadership position where he had overall accountability, as an account lead, for the execution of the Data Management strategy on numerous complex Oncology studies. Ashley joined the Oncology team within the Data Monitoring and Management department at Pfizer in 2018 and is currently an asset lead supporting the development of a number of key, pivotal compounds. Ashley is a business lead for Pfizer’s development and implementation of the Smart Data Query (SDQ) tool, an industry first leveraging AI/ML to hyper-accelerate complex data review and reconciliation activities. Ashley holds a Bachelor of Science degree in Biology from Sheffield Hallam University, UK.

Melissa Binz, Head of Standards and Data Conformity, Pfizer
Melissa is currently the Head of Standards and Data Conformity at Pfizer and has over 25 years of experience working in the life sciences industry supporting clinical research in the areas of statistics, statistical reporting and data management, including system implementation and quality management across the biometrics continuum. During this time, she has worked for global CROs, biotechs and large biopharmaceutical companies. Melissa currently leads the Clinical Data Interchange Standards Consortium’s (CDISC) Clinical Data Acquisition Standards Harmonization (CDASH) team and has been an active member since 2006. Ms. Binz has a bachelor’s degree in mathematics from Millersville University and a master’s degree in computer science from Villanova University.


Participants are eligible to receive CEUs upon attendance and successful completion of a web-based assessment within 30 days after the webinar. CEUs are not granted after the 30-day assessment deadline.

SCDM is authorized by IACET to offer 0.2 CEUs for this program.


Registration Member Non-member
Individual $360 $420
Group (max. 10 ppl.) $960 $1,140

Group Registration Policy:
Any group registration allows up to 10 people to attend the webinar and to complete the webinar assessment. Credits will be granted on an individual basis upon successful completion of the assessment by the registered participants.

Refund Policy: Participants will receive a full refund if notice is provided in writing via post or email one week prior to the webinar date. If cancellation occurs within the week prior the webinar, participants will be allowed to apply 50% of the webinar fee to the next offering of the same webinar. No refunds will be offered after that time.

Need Support?
Technical support:
Click on the help button on the bottom right, select contact support and email the BlueSky team with any technical issues.
Otherwise e-mail directly to or call +1-888-705-6002 for immediate help.
General support:
The SCDM Learning team is here to help. Contact us at or call +32 232 024 87